Drug Trial Radar · NCT00098358
Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Feb 7, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Actual
Start
Nov 2004
Primary completion
Not stated
Study completion May 2005
Sponsor
- Lead sponsor
- Critical TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4) is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase. This study will test the safety and efficacy of zileuton in the treatment of facial acne.
Conditions
- Acne Vulgaris
Interventions
ZileutonDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in number of inflammatory lesions
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Therapeutics Clinical Research
San Diego, California
MedaPhase, Inc.
Newnan, Georgia
Dermatology Specialists, PSC
Louisville, Kentucky
Minnesota Clinical Study Center
Fridley, Minnesota
Academic Dermatology Associates
Albuquerque, New Mexico
SUNY Downstate Medical Center
Brooklyn, New York
Dermatology Associates of Rochester
Rochester, New York
Milton S. Hersey Medical Center
Hersey, Pennsylvania
Rivergate Dermatology
Goodlettsville, Tennessee
DermResearch, Inc.
Austin, Texas
J&S Studies, Inc.
Bryan, Texas
Virginia Clinical Research, Inc.
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.